- Brand names:
- Pharmaceutical Company:
- Condition/Indication: High grade epithelial ovarian, fallopian tube, or primary peritoneal cancer
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 1797KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 484KB)
Niraparib – July 2021
Niraparib: Capsule 100 mg; Zejula®
Last updated
26 November 2021